SAIPARENT
Sai Parenterals Limited
Pharmaceutical formulations including injectables and oral dosages
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
saiparenterals.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Sai Parenterals makes injectable and oral pharmaceutical formulations, selling to government agencies and hospitals in India and, through its Australian subsidiary Noumed, private-label medicines to Australian pharmacy chains.
Company snapshot
76thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓88% of operating profit came in as cash over the last three years — profits are backed by real cash.
- ✗Interest coverage of 1.2x — earnings barely cover interest payments, which is a warning sign.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 96 Cr | 198 Cr | 179 Cr |
| Operating expenses (approx.) | 100 Cr | 172 Cr | 155 Cr |
| EBITDA | -4 Cr | 26 Cr | 24 Cr |
| OPM % | -3.7% | 13.2% | 13.2% |
| Other income | 3 Cr | 3 Cr | 4 Cr |
| Interest | 5 Cr | 8 Cr | 9 Cr |
| Depreciation | 6 Cr | 8 Cr | 8 Cr |
| Profit before tax | -12 Cr | 12 Cr | 10 Cr |
| Tax % | 42.7% | -6.2% | 19.1% |
| Net profit | -7 Cr | 13 Cr | 8 Cr |
| EPS (₹) | ₹-2.22 | ₹4.02 | ₹1.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 97 Cr | 154 Cr | 163 Cr | 381 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 79 Cr | 122 Cr | 124 Cr | 342 Cr | Sign in free for the trailing twelve months |
| EBITDA | 18 Cr | 32 Cr | 39 Cr | 39 Cr | Sign in free for the trailing twelve months |
| OPM % | 18.2% | 20.6% | 24.1% | 10.2% | Sign in free for the trailing twelve months |
| Other income | 0.23 Cr | 1 Cr | 0.64 Cr | 9 Cr | Sign in free for the trailing twelve months |
| Interest | 5 Cr | 11 Cr | 12 Cr | 18 Cr | Sign in free for the trailing twelve months |
| Depreciation | 6 Cr | 9 Cr | 8 Cr | 17 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 7 Cr | 13 Cr | 20 Cr | 12 Cr | Sign in free for the trailing twelve months |
| Tax % | 39.7% | 33.0% | 27.5% | -19.5% | Sign in free for the trailing twelve months |
| Net profit | 4 Cr | 8 Cr | 14 Cr | 14 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | — | — | ₹5.43 | ₹4.36 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 7 Cr | 13 Cr | 13 Cr | 22 Cr |
| Reserves | 24 Cr | 61 Cr | 80 Cr | 469 Cr |
| Borrowings | 69 Cr | 119 Cr | 94 Cr | 319 Cr |
| Other liabilities | 34 Cr | 73 Cr | 83 Cr | 610 Cr |
| Total liabilities | 134 Cr | 268 Cr | 272 Cr | 1,424 Cr |
| Fixed assets (net) | 44 Cr | 60 Cr | 43 Cr | 62 Cr |
| CWIP | 2 Cr | — | 0.50 Cr | 212 Cr |
| Investments | — | — | — | 0 Cr |
| Loans & advances | — | — | — | 3 Cr |
| Inventories | 13 Cr | 37 Cr | 51 Cr | 172 Cr |
| Trade receivables | 61 Cr | 127 Cr | 127 Cr | 181 Cr |
| Cash & bank | 0.17 Cr | 4 Cr | 2 Cr | 417 Cr |
| Other assets | 14 Cr | 39 Cr | 49 Cr | 378 Cr |
| Total assets | 134 Cr | 268 Cr | 272 Cr | 1,424 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operating activity | -13 Cr | -30 Cr | 33 Cr | 93 Cr |
| Cash from investing | -19 Cr | -46 Cr | 0.43 Cr | -274 Cr |
| Cash from financing | 24 Cr | 79 Cr | -36 Cr | 596 Cr |
| Net cash flow | -8 Cr | 2 Cr | -2 Cr | 415 Cr |
| Free cash flow (OCF − Capex) | -30 Cr | -72 Cr | — | 28 Cr |
Ratios
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | 12.1% | 12.1% | 16.8% | 3.7% |
| ROE % | 13.9% | 11.0% | 15.1% | 2.9% |
| Debtor days | 230 | 302 | 282 | 173 |
| Inventory days | 74 | 143 | 193 | 263 |
| Days payable | 125 | 202 | 219 | 227 |
| Cash conversion cycle | 179 | 242 | 257 | 208 |
| OCF / EBITDA % | -72.6% | -94.0% | 84.2% | 240.5% |
| OCF / EBITDA % (3 years) | — | — | -10.6% | 87.9% |
| Debt / equity | 2.18 | 1.59 | 1.00 | 0.65 |
| Current ratio | 1.07 | 1.23 | 1.23 | 1.44 |
| Net debt / EBITDA | 3.88 | 3.61 | 2.33 | -2.52 |